The new wave of immunotherapy antibodies in cancers and rare haematological diseases
A clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies
Welcome to ElsaLys Biotech
ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.
Today ELSALYS BIOTECH is conducting 5 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.
The company is acting today in 3 main medical fields :